Objectives: Erythrocyte membrane disorders are caused by a deficiency of structural proteins in the erythrocyte membrane. Accurate differential diagnosis within this group of disorders (is essential for appropriate management. The eosin-5′-maleimide (EMA) binding assay is a novel test that is used for the differential diagnosis of erythrocyte membrane disorders. In this study, we have examined and reported blood counts, reticulocyte indices, and the EMA binding assay results with clinical findings of cases admitted to our laboratory for suspected red blood cell (RBC) membrane disorder. Methods: We performed the EMA binding assay on the blood samples of 103 patients who were screened for hereditary erythrocyte membrane disorders at the Flow Cytometry Laboratory of Ankara Numune Training and Research Hospital. The total cohort was grouped as patients with hereditary spherocytosis (HS) (n=36) and control group (patients without erythrocyte membrane disorders (n=60), and non-HS patients with a preliminary diagnosis of hemolytic anemia (n=7). The control group included during data collection, the results of the EMA binding assay were recorded along with demographic features, clinical information, morphologic features, blood count parameters, RBC and reticulocyte indices, and a conventional osmotic fragility (OF) test. Receiver Operating Characteristics (ROC) analyses were performed to evaluate the diagnostic accuracy of the EMA binding assay and reticulocyte parameters. Results: Both EMA testing and flow cytometric (FC) OF test were significantly lower in overall (n=36), ≤10-year-old (n=12), and >10-year-old (n=24) patients with HS than in healthy controls (p<0.001). The EMA binding assay had 100 % sensitivity and specificity in screening HS. Conclusions: Combined with conventional blood tests, clinical findings, and medical history, the EMA binding assay is a reliable and convenient tool for screening for HS and differentiating hereditary erythrocyte membrane disorders.
10 February 2025 in International Journal of Hematology-Oncology and Stem Cell Research
Blastic plasmacytoid dendritic cell neoplasms (BPDCN) are rare, aggressive hematologic neoplasms. Awareness about this neoplasm has increased after it was defined as a clonal plasmacytoid dendritic cell disease under histiocytic/dendritic cell neoplasms in the World Health Organization 2022 classification of myeloid and Histiocytic/Dendritic Neoplasms1. Therapies include chemotherapy or immunotherapy2-4 though stem cell transplantation (SCT) is the best consolidative approach in eligible patients5. Here, we present one intensive therapy-ineligible and two intensive-therapy-eligible patients with different presentations of BPDCN.
Objective: Chronic age related medical problems and blood-borne viral infections may be overlooked by the clinicians in Hemophilia A, and likewise Hemophilia A patients may not be concerned sufficiently about their medical conditions other than hemophilia A. We aimed to investigate the comorbidities and the blood borne viral infections observed in the adult hemophilia A patients in our tertiary center. Methods: Adult hemophilia A patients diagnosed between the years of 1961 and 2007 were reviewed retrospectively for analysis. Demographic data, comorbidities, body mass indexes and markers for viral infections were recorded. Results: A total of 26 patients were in strict follow up in our Hemophilia A cohort. Hypertension (19%) and nephrolithiasis (19%) were the most common comorbidities. Being obese (Body Mass Index≥30 kg/m2) was not found as a risk factor for diabetes (p=1.000), hypertension (p=0.280), and hepatosteatosis (p=0.546). Two cases had positive Hepatitis B virus and 2 had positive Hepatitis C virus load. Conclusion: The results of our present study revealed that hypertension unawareness was high and incident diabetes is also a problem for Hemophilia A patients. Clinicians should be aware of blood-borne pathogens and other comorbidities; they should perform screening tests.